Company news

Bionano Genomics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Bionano Genomics Reports Preliminary Fourth Quarter and Full-Year 2021 Results

January 11, 2022

Bionano Genomics Announces Publication of Interim Readout from the Consortium Conducting a Postnatal Clinical Trial Intended to Support Establishing Optical Genome Mapping as Part of Standard of Care in Genetic Disease Diagnosis

January 9, 2022

Bionano Genomics Announces the Final Speaker Lineup for 2022 Symposium

January 6, 2022

Bionano Announces Prototype for its Next Single Molecule Imaging System for OGM

December 28, 2021

Bionano Genomics Appoints Vince Wong to its Board of Directors

December 21, 2021

Bionano Genomics Announces the Launch of Version 6.1 of BioDiscovery’s NxClinical Software for Genome Analysis with Expanded Capabilities for Visualization, Interpretation and Reporting of Next-Generation Sequencing Data in Genetic Diseases and Cancer

December 15, 2021

Bionano Genomics Announces 2022 Symposium Featuring Four Consecutive Days of OGM Presentations and Live Panel Discussions Delivered by 25 Different Customers Across a Wide Range of Genetic Disease and Cancer Applications

December 8, 2021

Bionano Genomics Announces Publication of Study Evaluating Optical Genome Mapping for High Throughput Characterization of Cytogenomic Heterogeneity in MDS

December 7, 2021

Bionano Genomics Appoints Dr. Keith Gligorich, Seasoned Leader in CLIA-Certified CAP-Accredited Lab Operations, as VP Operations for Bionano Laboratories

November 28, 2021

Bionano Genomics Announces Peer-Reviewed Publication from Johns Hopkins University Outlining a Stepwise Approach to the Adoption of Optical Genome Mapping for Cancer Analysis

November 21, 2021

Bionano Genomics Announces Extensive Lineup of Content to be Presented at the Annual Meeting of the Association for Molecular Pathology Featuring Optical Genome Mapping Across a Broad Range of Clinical Research Applications

November 14, 2021

Bionano Genomics Reports Third Quarter 2021 Financial Results and Highlights Recent Business Progress

November 3, 2021

Bionano Genomics Announces Major Updates to Its Solve™ and Access™ Data Solutions Adding Significant New Variant Detection, Analysis and Reporting Capabilities for Optical Genome Mapping on the Saphyr® System

November 2, 2021

Bionano Genomics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 1, 2021

Bionano Genomics Announces American Society of Human Genetics Presentations Featuring Optical Genome Mapping for Genetic Disease and Cancer Research Applications

October 14, 2021

Bionano Genomics to Acquire BioDiscovery, Furthering Bionano’s Vision of Creating the Most Comprehensive Variant Analysis Platform in Genomics

October 11, 2021

Bionano Genomics Expands Commercial Leadership Team to Accelerate Growth of Saphyr® and Bolster Customer Support and Experience Globally

October 5, 2021

Bionano Genomics Announces ESHG Lineup Featuring 11 Customer Presentations of OGM Data Spanning Three Major Clinical Research Areas of Application from 10 Institutions and Six Countries

August 25, 2021

Bionano Genomics Reports Second Quarter 2021 Financial Results and Highlights Recent Business Progress

August 3, 2021

Bionano Genomics to Report Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 4, 2021

July 27, 2021

Bionano Genomics Announces a Record Number of Optical Genome Mapping Presentations Scheduled to Appear at the Annual Cancer Genomics Consortium Meeting from August 1st - 4th, 2021

July 26, 2021

Bionano’s Optical Genome Mapping Reveals New Insights and Prognostic Capabilities Compared to Traditional Cytogenetics Techniques in Several Leukemia Clinical Research Studies Presented at the ECA

July 13, 2021

Bionano Genomics Announces Back-to-Back Publications in the American Journal of Human Genetics that Compare Optical Genome Mapping to Traditional Methods for Structural Variant Analysis in Inherited Genetic Disease and Hematological Malignancies

July 6, 2021

Bionano Genomics Announces Significant Progress in China with WeHealth Shanghai’s Adoption of Bionano’s Saphyr System and the Demonstration by Various Institutions of Optical Genome Mapping in Reproductive Health and Genetics

July 5, 2021

Bionano Genomics Added to Membership of US Small-Cap Russell 2000® Index

June 27, 2021

Bionano Genomics Appoints Richard Shippy, Former Affymetrix, Illumina and Cradle Executive, as its Chief Business Officer

June 13, 2021

Bionano Genomics Appoints Jason Priar, Former GeneDx, Sema4 and PerkinElmer Genomics Sales Leader, as its Chief Commercial Officer

June 6, 2021

Bionano Genomics Reports First Quarter 2021 Financial Results and Highlights Recent Business Progress

May 12, 2021

Bionano Genomics Announces Issuance of US Patent for Targeted Labeling Strategy to Complement Whole Genome Analysis Using Optical Genome Mapping

May 3, 2021

Bionano Genomics Announces Publication of New Approach to Study DNA Replication Using Optical Genome Mapping With Saphyr, Potentially Supporting Development of Cancer Drugs Targeting Replication Pathways

April 21, 2021

Bionano Genomics Announces Sites within the UK’s National Health System have Adopted its Saphyr System for Optical Genome Mapping

April 20, 2021

Bionano Genomics Announces Pre-Clinical Evaluation of Optical Genome Mapping by the Foundation for Embryonic Competence

April 13, 2021

Bionano Genomics Announces Record Number of Presentations on Optical Genome Mapping and Structural Variation at the 2021 Annual Clinical Genetics Meeting of the ACMG

April 11, 2021

Bionano Genomics Announces Presentations on Optical Genome Mapping at the American Association for Cancer Research (AACR) Annual Meeting 2021

April 6, 2021

Bionano Genomics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020 and Highlights Recent Corporate Updates

March 22, 2021

Bionano Genomics to Report Fourth Quarter and Year End 2020 Financial Results and Host a Conference Call and Webcast on March 23rd, 2021

March 8, 2021

Bionano Publishes Method for Identifying Genes Likely to Cause Neurological Diseases Based on a Model Developed by Lineagen to Improve Interpretation of Variants of Unknown Significance

February 21, 2021

Bionano Significantly Reduces Analysis Cost and Time to Actionable Results with Update to its Cloud Compute

January 25, 2021

Bionano Genomics Announces Closing of $230 Million Underwritten Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

January 24, 2021

Bionano Genomics Announces Pricing of $200 Million Underwritten Public Offering of Common Stock

January 19, 2021

Bionano Genomics Announces Proposed Underwritten Public Offering of Common Stock

January 18, 2021

Bionano Genomics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

January 12, 2021

Bionano Genomics Announces Closing of $101.8 Million Underwritten Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

January 11, 2021

Bionano Genomics Announces the Kick-Off of its Next-Generation Cytogenomics Symposium, The Largest Event Yet to Showcase Saphyr’s Utility in Genome Analysis for Genetic Disease and Cancer

January 9, 2021

Bionano Genomics Announces Pricing of $88.5 Million Underwritten Public Offering of Common Stock

January 7, 2021

Bionano Genomics Achieves Key Milestone with Software Update for its Saphyr System that Increases Throughput to 96 Human Genomes Per Week and Adds Saphyr Assure for Monitoring System Health

December 20, 2020

Bionano Genomics Reports Third Quarter 2020 Financial Results and Provides Business Update

November 11, 2020

Bionano Genomics Releases Major Update to Its Suite of Software Tools That Simplifies Clinical Analysis, Reduces Time to Actionable Results and Makes Adoption by Clinical Labs Easier

October 20, 2020

Bionano Genomics Announces Positive Outcome of Its Special Stockholder Meeting

September 29, 2020

Bionano Genomics Announces Continued Expansion of Global Business with Adoption of Saphyr for Next-Generation Cytogenomics in Eastern Europe and Australia

September 28, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 18 decks. Every deck is listed under its year.